SG47948A1 - Compounds for the treatment of neurodegenerative disorders - Google Patents

Compounds for the treatment of neurodegenerative disorders

Info

Publication number
SG47948A1
SG47948A1 SG1996005610A SG1996005610A SG47948A1 SG 47948 A1 SG47948 A1 SG 47948A1 SG 1996005610 A SG1996005610 A SG 1996005610A SG 1996005610 A SG1996005610 A SG 1996005610A SG 47948 A1 SG47948 A1 SG 47948A1
Authority
SG
Singapore
Prior art keywords
treatment
neurodegenerative disorders
compounds
pyridineethanamine
alpha
Prior art date
Application number
SG1996005610A
Other languages
English (en)
Inventor
Michael Balestra
Ronald Conrad Griffith
Robert John Murray
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929207339A external-priority patent/GB9207339D0/en
Priority claimed from GB929208290A external-priority patent/GB9208290D0/en
Application filed by Astra Ab filed Critical Astra Ab
Publication of SG47948A1 publication Critical patent/SG47948A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
SG1996005610A 1992-04-03 1993-04-01 Compounds for the treatment of neurodegenerative disorders SG47948A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929207339A GB9207339D0 (en) 1992-04-03 1992-04-03 Pharmaceutical compound
GB929208290A GB9208290D0 (en) 1992-04-15 1992-04-15 Pharmaceutical compound having neuroprotective properties

Publications (1)

Publication Number Publication Date
SG47948A1 true SG47948A1 (en) 1998-04-17

Family

ID=26300643

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996005610A SG47948A1 (en) 1992-04-03 1993-04-01 Compounds for the treatment of neurodegenerative disorders

Country Status (28)

Country Link
EP (1) EP0633879B1 (da)
JP (2) JP3120810B2 (da)
KR (1) KR100259567B1 (da)
CN (1) CN1044367C (da)
AT (1) ATE163925T1 (da)
AU (2) AU3897693A (da)
CA (1) CA2133427C (da)
CZ (1) CZ288519B6 (da)
DE (1) DE69317411T2 (da)
DK (1) DK0633879T3 (da)
DZ (1) DZ1677A1 (da)
ES (1) ES2115055T3 (da)
FI (1) FI105025B (da)
HU (1) HU211529A9 (da)
IL (1) IL105276A (da)
MA (1) MA22866A1 (da)
MX (1) MX9301935A (da)
MY (1) MY110149A (da)
NO (1) NO302170B1 (da)
NZ (1) NZ251384A (da)
PL (1) PL180014B1 (da)
RU (1) RU2128650C1 (da)
SG (1) SG47948A1 (da)
SK (1) SK281258B6 (da)
TW (1) TW282455B (da)
UA (1) UA29437C2 (da)
WO (1) WO1993020052A1 (da)
ZA (1) ZA932415B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320273D0 (en) * 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
SG52662A1 (en) * 1988-08-12 1998-09-28 Astra Ab Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties
ZA942140B (en) * 1993-04-01 1994-10-03 Fisons Corp Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901237D0 (sv) * 1999-04-06 1999-04-06 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
HUP0202143A3 (en) * 1999-07-28 2003-12-29 Ortho Mcneil Pharm Inc Amine and amide derivatives as ligands for the neuropeptide y y5 receptor pharmaceutical compositions containing them and their use
WO2007017652A2 (en) * 2005-08-10 2007-02-15 Astrazeneca Ab Arylakylamines for the treatment of cancer
BRPI0923476A2 (pt) * 2008-12-24 2016-01-19 Astrazeneca Ab composto, métodos para tratar depressão em um ser humano, e grande distúrbio depressivo, e, composição farmacêutica
JP2015501652A (ja) * 2011-12-14 2015-01-19 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag Gabr−a2診断
SI3066091T1 (sl) 2013-11-05 2019-09-30 Astrazeneca Ab NMDA antagonist predzdravila
AU2021297823A1 (en) * 2020-06-23 2023-02-16 Biohaven Therapeutics Ltd. Topical formulations of (1S)-1-phenyl-2-pyridin-2-ylethanamine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA889252B (en) * 1987-12-11 1990-08-29 Syntex Lab Neuroprotective compounds
SG52662A1 (en) * 1988-08-12 1998-09-28 Astra Ab Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties

Also Published As

Publication number Publication date
JP2000319259A (ja) 2000-11-21
HK1009331A1 (en) 1999-05-28
DZ1677A1 (fr) 2002-02-17
TW282455B (da) 1996-08-01
RU94042465A (ru) 1996-07-20
RU2128650C1 (ru) 1999-04-10
UA29437C2 (uk) 2000-11-15
ES2115055T3 (es) 1998-06-16
JP3120810B2 (ja) 2000-12-25
ZA932415B (en) 1993-10-22
CA2133427A1 (en) 1993-10-14
CZ240994A3 (en) 1995-12-13
MX9301935A (es) 1994-08-31
SK281258B6 (sk) 2001-01-18
AU7545696A (en) 1997-02-13
KR100259567B1 (ko) 2000-07-01
NO943645D0 (no) 1994-09-30
FI944546L (fi) 1994-09-30
WO1993020052A1 (en) 1993-10-14
CN1044367C (zh) 1999-07-28
NO302170B1 (no) 1998-02-02
DK0633879T3 (da) 1998-09-28
AU3897693A (en) 1993-11-08
HU211529A9 (en) 1995-11-28
NO943645L (no) 1994-11-16
DE69317411D1 (de) 1998-04-16
DE69317411T2 (de) 1998-07-30
CA2133427C (en) 2003-06-10
JPH07505385A (ja) 1995-06-15
IL105276A (en) 1997-06-10
EP0633879A1 (en) 1995-01-18
MY110149A (en) 1998-02-28
SK117794A3 (en) 1995-05-10
CZ288519B6 (cs) 2001-07-11
PL180014B1 (pl) 2000-11-30
FI944546A0 (fi) 1994-09-30
CN1081669A (zh) 1994-02-09
NZ251384A (en) 1996-10-28
FI105025B (fi) 2000-05-31
AU705419B2 (en) 1999-05-20
EP0633879B1 (en) 1998-03-11
ATE163925T1 (de) 1998-03-15
MA22866A1 (fr) 1993-12-31
IL105276A0 (en) 1993-08-18

Similar Documents

Publication Publication Date Title
AU610036B2 (en) Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis inflammation and as immunosuppressants
IL110204A0 (en) Novel indolene derivatives, processes for their preparation and their use for the treatment of cns disorders
WO1993000094A3 (en) Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine
ZA928158B (en) Cytotoxic bicyclo[7.3.1]tridec-4-ene-2,6-diyne compounds and process for the preparation thereof.
PH31073A (en) Pharmaceutical composition and process for the preparation thereof.
ZA932415B (en) Compounds for the treatment of neurodegenerative disorders
EP0626162A3 (de) Krankenbett.
CA2135709A1 (en) Melatonin derivatives for use in treating sleep disorders
EP0592903A3 (en) Use of Ancrod in the manufacture of medications for the treatment of restenosis.
CA2135710A1 (en) Melatonin derivatives for use in treating desynchronization disorders
ZA933151B (en) Cycloheptimidazole derivatives, method of manufacturing the same and therapeutic agents containing these compounds.
EP0638357A3 (de) Vorrichtung zur kontinuierlichen Herstellung von Polyacetalen und ihre Verwendung.
AU6581294A (en) Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
EP0583136A3 (en) Piperidino-3,4-dihydrocarbostyryl compounds for the treatment of ischemic disorders
GR3036226T3 (en) 6-methoxy-1h-benzotriazole-5-carboxamide derivatives, process for producing the same, and medicinal composition containing the same
IL99236A0 (en) Pharmaceutical composition for the topical treatment of psoriasis
AU3084992A (en) 1,4-dihydropyridines for use in the treatment of dermatosis
AU4825993A (en) New compounds for use in the treatment of cancer
GB2270313B (en) 1,3,4-Benzotriazepin-5 (4H)-one derivatives and process for the preparation thereof
GB9816517D0 (en) 2,3-distributed cyclopentanone derivatives process for producing the same and medicinal use theeof
AU6242294A (en) 3,3-disubstituted tri- and tetracyclic indolin-2-ones useful for the treatment of cognitive disorders
AU7183298A (en) Melatonin derivatives for use in treating desynchronization disorders
GR920100423A (el) Ανταγωνιστές 5-ΗΤ4 κινολιζιδινυλ εστέρος.
ES1023651Y (es) "barandilla de cama, perfeccionada"
ZA932062B (en) Indole and indazole derivatives, for the treatment and prophylaxis of cerabral disorders, their preparation and their use